We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu
IMPORTANT: Due to the lapse in government funding, the information on this web site may not be up to date, transactions submitted via the web site may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Pentostatin, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00541034
Recruitment Status : Completed
First Posted : October 8, 2007
Results First Posted : February 27, 2017
Last Update Posted : August 11, 2017
Information provided by (Responsible Party):

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment;   Masking: None (Open Label);   Primary Purpose: Treatment
Conditions: Leukemia
Interventions: Biological: rituximab
Drug: cyclophosphamide
Drug: pentostatin

  Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
All Patients All patients who received cyclophosphamide, pentostatin and rituximab

Participant Flow:   Overall Study
    All Patients
Non-Compliance                3 

  Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
All Patients All patients who received cyclophosphamide, pentostatin and rituximab

Baseline Measures
   All Patients 
Overall Participants Analyzed 
[Units: Participants]
[Units: Participants]
Count of Participants
<=18 years      0   0.0% 
Between 18 and 65 years      31  63.3% 
>=65 years      18  36.7% 
Sex: Female, Male 
[Units: Participants]
Count of Participants
Female      12  24.5% 
Male      37  75.5% 

  Outcome Measures

1.  Primary:   Overall Objective Response   [ Time Frame: 2 years ]

  Serious Adverse Events

  Other Adverse Events

  Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

  More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.

Results Point of Contact:  
Name/Title: Dr. Renier Brentjens
Organization: Memorial Sloan Kettering Cancer Center
phone: 1212-639-7053
e-mail: brentjer@mskcc.org

Responsible Party: Memorial Sloan Kettering Cancer Center
ClinicalTrials.gov Identifier: NCT00541034     History of Changes
Other Study ID Numbers: 05-051
P30CA008748 ( U.S. NIH Grant/Contract )
First Submitted: October 5, 2007
First Posted: October 8, 2007
Results First Submitted: January 9, 2017
Results First Posted: February 27, 2017
Last Update Posted: August 11, 2017